CN115397811B - 与atp结合位点结合的异吲哚啉衍生物 - Google Patents

与atp结合位点结合的异吲哚啉衍生物 Download PDF

Info

Publication number
CN115397811B
CN115397811B CN202180023267.0A CN202180023267A CN115397811B CN 115397811 B CN115397811 B CN 115397811B CN 202180023267 A CN202180023267 A CN 202180023267A CN 115397811 B CN115397811 B CN 115397811B
Authority
CN
China
Prior art keywords
formula
methyl
piperazin
dihydroxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180023267.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115397811A (zh
Inventor
朱利安·布拉格
乔纳森·理查德·安东尼·罗菲
保罗·科林·迈克尔·温希普
加雷斯·威廉·兰利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naio Finlay Co ltd
Original Assignee
Naio Finlay Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2000789.4A external-priority patent/GB202000789D0/en
Priority claimed from GBGB2003559.8A external-priority patent/GB202003559D0/en
Application filed by Naio Finlay Co ltd filed Critical Naio Finlay Co ltd
Publication of CN115397811A publication Critical patent/CN115397811A/zh
Application granted granted Critical
Publication of CN115397811B publication Critical patent/CN115397811B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180023267.0A 2020-01-20 2021-01-20 与atp结合位点结合的异吲哚啉衍生物 Active CN115397811B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2000789.4A GB202000789D0 (en) 2020-01-20 2020-01-20 Novel probe molecules
GB2000789.4 2020-01-20
GBGB2003559.8A GB202003559D0 (en) 2020-03-11 2020-03-11 Novel probe molecules
GB2003559.8 2020-03-11
PCT/GB2021/050122 WO2021148786A1 (en) 2020-01-20 2021-01-20 Isoindoline derivatives which bind to an atp binding site

Publications (2)

Publication Number Publication Date
CN115397811A CN115397811A (zh) 2022-11-25
CN115397811B true CN115397811B (zh) 2025-05-23

Family

ID=74285509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023267.0A Active CN115397811B (zh) 2020-01-20 2021-01-20 与atp结合位点结合的异吲哚啉衍生物

Country Status (7)

Country Link
US (1) US12517130B2 (https=)
EP (1) EP4093731A1 (https=)
JP (1) JP7671308B2 (https=)
CN (1) CN115397811B (https=)
AU (1) AU2021211925A1 (https=)
CA (1) CA3168495A1 (https=)
WO (1) WO2021148786A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021211925A1 (en) 2020-01-20 2022-08-25 Neophore Limited Isoindoline derivatives which bind to an ATP binding site
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202110373D0 (en) * 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
GB202307924D0 (en) * 2023-05-26 2023-07-12 Neophore Ltd Inhibitor compounds
CN117586174B (zh) * 2024-01-19 2024-05-10 中国药科大学 用于诊断结直肠癌的近红外荧光探针及其制法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118830A1 (en) * 2017-12-14 2019-06-20 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2009060835A1 (ja) 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP3738594A1 (en) * 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20210275630A1 (en) 2016-04-18 2021-09-09 Phoremost Limited Inactivation of dna repair as an anticancer therapy
MA45670A (fr) 2016-07-13 2019-05-22 Vertex Pharma Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
EP3568128B1 (en) 2017-01-12 2022-07-06 The University of Kansas Hsp90b n-terminal isoform-selective inhibitors
WO2019014600A1 (en) 2017-07-13 2019-01-17 Plex Pharmaceuticals, Inc. TREATMENT OF ASSOCIATION FOR THE TREATMENT OF CANCER
EP3773670A4 (en) 2018-04-05 2022-03-09 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CA3099155A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11026963B2 (en) 2018-07-11 2021-06-08 Rubedo Life Sciences, Inc. Senolytic compositions and uses thereof
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
AU2021211925A1 (en) 2020-01-20 2022-08-25 Neophore Limited Isoindoline derivatives which bind to an ATP binding site
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
GB202300881D0 (en) 2023-01-20 2023-03-08 Neophore Ltd Inhibitor compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118830A1 (en) * 2017-12-14 2019-06-20 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Xuorescence polarization assay for inhibitors of Hsp90;R. Howes等;《Analytical Biochemistry》;第350卷(第2期);全文 *

Also Published As

Publication number Publication date
AU2021211925A1 (en) 2022-08-25
CN115397811A (zh) 2022-11-25
JP7671308B2 (ja) 2025-05-01
CA3168495A1 (en) 2021-07-29
EP4093731A1 (en) 2022-11-30
JP2023511229A (ja) 2023-03-16
US12517130B2 (en) 2026-01-06
US20230061002A1 (en) 2023-03-02
WO2021148786A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CN115397811B (zh) 与atp结合位点结合的异吲哚啉衍生物
DK2423201T3 (en) Luminescent macrocyclic lanthanide complexes
De León-Rodríguez et al. Highly regioselective N-trans symmetrical diprotection of cyclen
US6207831B1 (en) Fluorescent dyes (AIDA) for solid phase and solution phase screening
CN103819486B (zh) 标记血清糖原磷酸化酶浓度水平的光亲和标记探针分子、其制备方法及医药用途
US8461358B2 (en) Fluorescent probe for measuring protease
JP7523166B2 (ja) コロナウイルス３ｃｌプロテアーゼを標的とするｖｈｌリガンドに基づくｐｒｏｔａｃ、およびその調製方法と応用
JP7663498B2 (ja) 蛍光ｇｔｐ類似体および使用
Van De Langemheen et al. Polar hinges as functionalized conformational constraints in (bi) cyclic peptides
Liu et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study
EP2057279A2 (en) Bisubstrate fluorescent probe binding to protein kinases
Chen et al. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1
EP1670789B1 (en) Fluorescent probes for use in protein kinase inhibitor binding assay
JP4138331B2 (ja) リン酸イオンおよびリン酸化ペプチド用蛍光センサー
EP1923397B1 (en) Fluorinated amino acids and peptides
Inverarity et al. Marked small molecule libraries: a truncated approach to molecular probe design
JP6670502B2 (ja) 神経伝達物質受容体のリガンドスクリーニングシステムの開発
Wodtke et al. Solution-phase synthesis of the fluorogenic TGase 2 acyl donor Z-Glu (HMC)-Gly-OH and its use for inhibitor and amine substrate characterisation
Komarova et al. The synthesis of 1-oxa-9-azaspiro [5.5] undecane derivatives and optimization of antituberculosis activity thereof
Litwin I. Synthesis and Evaluation of Biologically Active Small Molecules. II. Synthesis of Novel Caspase Inhibitors
Huber et al. Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1)
Zheng Development of Lysine-Targeted Probes for Protein Kinases
Sorba et al. The cyano-NNO-azoxy function in the design of an irreversible label for α1 adrenoreceptors
De Stefano et al. Click chemistry approach to develop dual RGD integrin and gelatinase peptidomimetic inhibitors
EP4716533A2 (en) Fluorescent indicators for metal ion detection as substrates for a self-labeling enzyme

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant